Today at our booth
On the final day we had some great talks on PREOPANC-1, PRODIGE 7 and ASPECT. Although we’re sad to see ASCO 2018 draw to a close, it’s been a fantastic conference and we’re already looking forward to next year!
Preoperative chemoradiotherapy improves survival time for patients with pancreatic cancer
A randomized Phase III trial has indicated that patients who received a combination of chemotherapy with radiation (chemoradiotherapy) before surgery for pancreatic cancer had a better disease-free survival than those who started their treatment with surgery. Preliminary findings of the trial demonstrate that chemoradiotherapy prior to surgery might be beneficial for patients with pancreatic cancer, with results showing that the 2-year survival rate was higher for those who received this treatment plan.
High dose of Nexium® with aspirin reduces risk of developing esophageal cancer
Researchers have demonstrated that taking a high dose of esomeprazole (Nexium®) along with a low dose aspirin, for at least 7 years, can reduce the risk of develop a high-grade dyslplasia or esophageal cancer.
PRODIGE 7 demonstrates that HIPEC may not be necessary for CRC patients
The PRODIGE 7 randomized has demonstrated that for advanced colorectal cancer patients, hyperthermic intra-peritoneal chemotherapy delivered to the abdomen during surgery, may not be necessary.
Best of social media #ASCO18
It’s really quite amazing that the plenary talks at #ASCO18 are showing how we can spare women with breast cancer from chemo and spare patients with advanced RCC from nephrectomy. Precision medicine = what you need: no more, no less
— Lecia Sequist (@LeciaSequist) June 3, 2018
— Hamid Emamekhoo (@HamidEmamekhoo) June 3, 2018
How apt that #ASCO18 plenary begins with the testimony of patients. This isn’t about p values or stock prices. It’s about making people better.
— Mark Lewis (@marklewismd) June 3, 2018
— Monica M. Bertagnolli, MD (@ASCOPres) June 4, 2018
— Stephanie Graff, MD (@DrSGraff) June 4, 2018